Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1021 to 1035 of 1433 results for primary care

  1. MMprofiler for prognostic risk classification in multiple myeloma (MIB270)

    NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .

    Medtech innovation briefing
    Published
    10 August 2021

  2. Slide sheets for moving or repositioning a person: late-stage assessment (HTG745)

    Late-stage assessment (LSA) guidance on slide sheets for moving or repositioning a person.

    HealthTech guidance
    Published
    30 April 2025
    View recommendations

    Sections for HTG745

  3. Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

    Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.

    Technology appraisal guidance
    Published
    7 February 2024
    View recommendations

    Sections for TA950

  4. Fruquintinib for previously treated metastatic colorectal cancer (TA1079)

    Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    23 July 2025
    View recommendations

    Sections for TA1079

  5. Erenumab for preventing migraine (TA682)

    Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    10 March 2021
    View recommendations

    Sections for TA682

  6. Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (TA883)

    Evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have an autologous stem cell transplant.

    Technology appraisal guidance
    Published
    3 May 2023
    View recommendations

    Sections for TA883

  7. Ruxolitinib for treating polycythaemia vera (TA921)

    Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.

    Technology appraisal guidance
    Published
    18 October 2023
    View recommendations

    Sections for TA921

  8. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

    Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Last updated
    20 May 2024
    View recommendations

    Sections for TA155

  9. Indwelling urinary catheters: catheter selection:- For patients using a long-term indwelling urinary catheter, what is the clinical and cost effectiveness of impregnated versus hydrophilic versus silicone catheters in reducing symptomatic urinary tract infections, encrustations and/or blockages?

    urethral and suprapubic) are commonly used in both hospital and community care settings. Long-term catheterisation carries a significant...

    Research recommendation
    Published
    9 June 2015

  10. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

    Evidence summary
    Published
    10 February 2015

  11. The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care (CG20)

    This guideline has been updated and replaced by NICE guideline CG137.

    Clinical guideline
    Published
    27 October 2004

  12. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care (CG73)

    This guidance has been updated and replaced by NICE guideline CG182.

    Clinical guideline
    Published
    24 September 2008

  13. clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia (MIB278)

    NICE has developed a medtech innovation briefing (MIB) on clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia .

    Medtech innovation briefing
    Published
    30 November 2021

  14. Hand decontamination:- When clean running water is not available, what is the clinical and cost effectiveness of using wipes, gels, handrubs or other products to remove visible contamination?

    particularly affects ambulance service staff, who often provide emergency care at locations where running water is not available. No...

    Research recommendation
    Published
    9 June 2015

  15. Vascular access devices: skin decontamination:- What is the clinical and cost effectiveness of 2% chlorhexidine in alcohol versus 0.5% chlorhexidine in alcohol versus 2% chlorhexidine aqueous solution versus 0.5% chlorhexidine aqueous solution for cleansing skin (before insertion of peripheral vascular access devices [VADs] and during dressing changes of all VADs) in reducing VAD-related bacteraemia and VAD site infections?

    improved when a single solution is used for all aspects of VAD-related skin care. There is no direct evidence comparing different...

    Research recommendation
    Published
    9 June 2015